1. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.
- Author
-
Chan, Alexandre, Hertz, Daniel L, Morales, Manuel, Adams, Elizabeth J, Gordon, Sharon, Tan, Chia Jie, Staff, Nathan P, Kamath, Jayesh, Oh, Jeong, Shinde, Shivani, Pon, Doreen, Dixit, Niharkia, D'Olimpio, James, Dumitrescu, Cristina, Gobbo, Margherita, Kober, Kord, Mayo, Samantha, Pang, Linda, Subbiah, Ishwaria, Beutler, Andreas S, Peters, Katherine B, Loprinzi, Charles, and Lustberg, Maryam B
- Subjects
Humans ,Peripheral Nervous System Diseases ,Neurotoxicity Syndromes ,Genetic Predisposition to Disease ,Taxoids ,Vinca Alkaloids ,Antineoplastic Agents ,Bortezomib ,CIPN ,Chemotherapy-induced peripheral neuropathy ,Neuropathy ,Peripheral Neuropathy ,Neurodegenerative ,Genetics ,Cancer ,Neurosciences ,2.1 Biological and endogenous factors ,Oncology & Carcinogenesis ,Medical and Health Sciences ,Psychology and Cognitive Sciences - Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual's specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.
- Published
- 2019